Rhizen Pharma’s partnered asset Umbralisib gets US FDA accelerated nod for relapsed or… EP News Bureau Feb 9, 2021 Umbralisib is a novel, next generation, oral, once daily, inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1…
Rhizen Pharma gets USFDA approval for Phase I trials of COVID-19 drug Press Trust of India Dec 2, 2020 The initial study would evaluate single ascending doses of the RP7214 in healthy volunteers and that dosing is expected to…
